Drew Brian G, Calkin Anna C
Baker Heart Research Institute, Juvenile Diabetes Research Foundation Centre for Diabetes Complications, PO Box 6492, St Kilda Road Central, Melbourne 8008, Australia.
Curr Opin Investig Drugs. 2007 Apr;8(4):324-30.
Kozva Co Ltd, under license from Roche Holding AG, is developing K-111, an orally available peroxisome proliferator-activated receptor a ligand and insulin-potentiating agent, for the potential treatment of type 2 diabetes. Phase II clinical trials of K-111 are underway.
Kozva有限公司根据罗氏控股公司的许可，正在开发K-111，一种口服可用的过氧化物酶体增殖物激活受体α配体和胰岛素增强剂，用于潜在治疗2型糖尿病。K-111的II期临床试验正在进行中。
